Home › Merck Statement Regarding CUBICIN Patent Litigation
 

Keywords :   


Merck Statement Regarding CUBICIN Patent Litigation

2014-12-09 14:11:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Company Reaffirms Transaction To Proceed as Planned; Expected to Close in First Quarter of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orSteve Cragle, 908-740-1801orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: statement patent litigation merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.06US surgeon general wants social media warning labels
17.06Topigs Norsvin unveils new boar test and research center
17.06Pork producers lead freedom to farm defense
17.06Eastern North Pacific Tropical Weather Outlook
17.06Atlantic Tropical Weather Outlook
17.06Labour accuses Tories of planning unfunded tax cuts
17.06Petrol prices far higher than they should be, says RAC
17.06Farm Progress America, June 17, 2024
More »